CD19 and plasma cell myeloma: Preliminary CAR-iNKT therapies have employed various CAR-targeting antigens associated with cancer, including CD19 [44], B cell maturation antigen (BCMA) [45], and GD2 [46] for the treatment of B cell lymphoma, multiple myeloma, and neuroblastoma tumors, respectively.